Long-term follow-up of biomarkers of vascular calcification after switch from traditional hemodialysis to online hemodiafiltration

References

• Rennenberg RJ, Kessels AG, Schurgers LJ, et al. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag. 2009;5:185–197.
   PubMedGoogle Scholar
• Evrard S, Delanaye P, Kamel S, et al. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2015;438:401–414.
   PubMed Web of Science ®Google Scholar
• Schlieper G, Schurgers L, Brandenburg V, et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31:31–39.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
   PubMed Web of Science ®Google Scholar
• Jia T, Qureshi AR, Brandenburg V, et al. Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. Am J Nephrol. 2013;37:462–471.
   PubMed Web of Science ®Google Scholar
• Viegas CS, Rafael MS, Enriquez JL, et al. Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. Arterioscler Thromb Vasc Biol. 2015;2:399–408.
   Web of Science ®Google Scholar
• Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;3:357–366.
   Web of Science ®Google Scholar
• Lorenzen J, Krämer R, Kliem V, et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest. 2010;4:294–300.
   Web of Science ®Google Scholar
• Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, et al. Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2013;36:3766–3771.
   PubMed Web of Science ®Google Scholar
• Liu Y-P, Gu Y-M, Thijs L, et al. Inactive matrix Gla protein is causally related to health outcomes: a Mendelian randomization study in a Flemish population. Hypertension. 2015;65:463–470.
   PubMed Web of Science ®Google Scholar
• Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5:568–575.
   PubMed Web of Science ®Google Scholar
• Dalmeijer GW, van der Schouw YT, Vermeer C, et al. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem. 2013;24:624–628.
   PubMed Web of Science ®Google Scholar
• Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006;17:262–270.
   PubMed Web of Science ®Google Scholar
• Nascimento MM, Hayashi SY, Riella MC, et al. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res. 2014;47:995–1002.
   PubMed Web of Science ®Google Scholar
• Haarhaus M, Brandenburg V, Kalantar-Zadeh K, et al. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol. 2017;13:429–442.
   PubMed Web of Science ®Google Scholar
• Roy ME, Nishimoto SK. Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. Bone. 2002;31:296–302.
   PubMed Web of Science ®Google Scholar
• Ek-Rylander B, Andersson G. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res. 2010;316:443–451.
   PubMed Web of Science ®Google Scholar
• Halling Linder C, Ek-Rylander B, Krumpel M, et al. Bone alkaline phosphatase and tartrate-resistant acid phosphatase: potential co-regulators of bone mineralization. Calcif Tissue Int. 2017;101:92–101.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Lippi G, Danese E, et al. The role of osteoprotegerin in cardiovascular disease. Ann Med. 2013;45:254–264.
   PubMed Web of Science ®Google Scholar
• Viegas CS, Simes DC, Laizé V, et al. Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem. 2008;283:36655–36664.
   PubMed Web of Science ®Google Scholar
• Viegas CSB, Costa RM, Santos L, et al. Gla-rich protein function as an anti-inflammatory agent in monocytes/macrophages: implications for calcification-related chronic inflammatory diseases. PLoS One. 2017;12:e0177829.
   PubMed Web of Science ®Google Scholar
• Brylka L, Jahnen-Dechent W. The role of fetuin-A in physiological and pathological mineralization. Calcif Tissue Int. 2013;93:355–364.
   PubMed Web of Science ®Google Scholar
• Sardiwal S, Magnusson P, Goldsmith DJA, et al. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis. 2013;62:810–822.
   PubMed Web of Science ®Google Scholar
• Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens. 2010;23:586–591.
   PubMed Web of Science ®Google Scholar
• Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24:487–497.
   PubMed Web of Science ®Google Scholar
• Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013;28:192–202.
   PubMed Web of Science ®Google Scholar
• Uhlin F, Magnusson P, Larsson TE, et al. In the backwater of convective dialysis: decreased 25-hydroxyvitamin D levels following the switch to online hemodiafiltration. Clin Nephrol. 2015;83:315–321.
   PubMed Web of Science ®Google Scholar
• Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006;21:1293–1299.
   PubMed Web of Science ®Google Scholar
• Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 1995;41:1560–1566.
   PubMed Web of Science ®Google Scholar
• Sennels HP, Jacobsen S, Jensen T, et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest. 2007;67:821–835.
   PubMed Web of Science ®Google Scholar
• Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97:3357–3365.
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Bourron O, Vemeer C, et al. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol. 2014;13:85.
   PubMed Web of Science ®Google Scholar
• Gracia-Iguacel C, Gallar P, Qureshi AR, et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr. 2010;20:359–367.
   PubMed Web of Science ®Google Scholar
• Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011;22:387–395.
   PubMed Web of Science ®Google Scholar
• Boxma PY, van den Berg E, Geleijnse JM, et al. Vitamin K intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS One. 2012;7:e47991.
   PubMed Web of Science ®Google Scholar
• Grooteman MP, van den Dorpel MA, Bots ML, et al. CONTRAST Investigators: effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012;23:1087–1096.
   PubMed Web of Science ®Google Scholar
• Uhlin F, Holmar J, Yngman-Uhlin P, et al. Optical estimation of beta 2 microglobulin during hemodiafiltration – does it work? Blood Purif. 2015;40:113–119.
   PubMed Web of Science ®Google Scholar
• Canaud B, Morena M, Cristol JP, et al. Beta2-microglobulin, a uremic toxin with a double meaning. Kidney Int. 2006;69:1297–1299.
   PubMed Web of Science ®Google Scholar
• Cornelis T, Eloot S, Vanholder R, et al. Protein-bound uraemic toxins, dicarbonyl stress and advanced glycation end products in conventional and extended haemodialysis and haemodiafiltration. Nephrol Dial Transplant. 2015;30:1395–1402.
   PubMed Web of Science ®Google Scholar
• Magnusson P, Farley JR. Differences in sialic acid residues among bone alkaline phosphatase isoforms: a physical, biochemical, and immunological characterization. Calcif Tissue Int. 2002;71:508–518.
   PubMed Web of Science ®Google Scholar
• Bargnoux AS, Vetromile F, Kuster N, et al. Markers of bone remodeling are associated with arterial stiffness in renal transplanted subjects. J Nephrol. 2015;28:765–772.
   PubMed Web of Science ®Google Scholar
• Charitaki E, Davenport A. Does hemodiafiltration reduce vascular stiffness measured by aortic pulse wave velocity compared with high-flux hemodialysis? Hemodial Int. 2014;18:391–395.
   PubMed Web of Science ®Google Scholar
• Charitaki E, Belman D, Davenport A. Treatment with haemodiafiltration stabilises vascular stiffness (measured by aortic pulse wave velocity) compared to haemodialysis. Nephron Clin Pract. 2014;128:185–191.
   PubMedGoogle Scholar
• Höller U, Bakker SJL, Düsterloh A, et al. Micronutrient status assessment in humans: current methods of analysis and future trends. Trends Analyt Chem. 2018;102:110–122.
   Web of Science ®Google Scholar
• Braam L, Hoeks A, Brouns F, et al. Beneficial effects of vitamin K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004;91:373–380.
   PubMed Web of Science ®Google Scholar
• Knapen MHJ, Braam LAJLM, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015;113:1135–1144.
   PubMed Web of Science ®Google Scholar
• Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3–5. Pol Arch Med Wewn. 2015;125:631–640.
   PubMed Web of Science ®Google Scholar
• Singer RF. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial. 2013;26:40–46.
   PubMed Web of Science ®Google Scholar
• Caluwé R, Pyfferoen L, De Boeck K, et al. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J. 2016;9:273–279.
   PubMed Web of Science ®Google Scholar
• El-Shehaby AM, Zakaria A, El-Khatib M, et al. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest. 2010;70:575–582.
   PubMed Web of Science ®Google Scholar
• Mohamadpour AH, Abdolrahmani L, Mirzaei H, et al. Serum osteopontin concentrations in relation to coronary artery disease. Arch Med Res. 2015;46:112–117.
   PubMed Web of Science ®Google Scholar